Showing results (581-590 of 782) with videos related to
Sort By:
Pageof 79
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|June 12, 2016
Phase 1 Study of Tabalumab, a Human Anti-B-Cell Activating Factor Antibody, and Bortezomib in Patients with Relapsed/Refractory Multiple MyelomaNoopur S Raje, Edward A Faber, Paul G Richardson, et al.Biology of Blood and Marrow Transplantation : Journal of the American Society for Blood and Marrow Transplantation|April 24, 2020
Long-Term Follow-up of CALGB (Alliance) 100001: Autologous Followed by Nonmyeloablative Allogeneic Transplant for Multiple MyelomaSarah A Holstein, Vera J Suman, Kouros Owzar, et al.Molecular Cancer Therapeutics|April 8, 2010
Dual inhibition of akt/mammalian target of rapamycin pathway by nanoparticle albumin-bound-rapamycin and perifosine induces antitumor activity in multiple myelomaDiana Cirstea, Teru Hideshima, Scott Rodig, et al.Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|March 19, 2008
Resveratrol exerts antiproliferative activity and induces apoptosis in Waldenström's macroglobulinemiaAldo M Roccaro, Xavier Leleu, Antonio Sacco, et al.Journal of Biomedical Optics|February 2, 2011
Optical techniques for tracking multiple myeloma engraftment, growth, and response to therapyJudith M Runnels, Alicia L Carlson, Costas Pitsillides, et al.Blood|July 24, 2012
Canonical and noncanonical Hedgehog pathway in the pathogenesis of multiple myelomaSimona Blotta, Jana Jakubikova, Teresa Calimeri, et al.Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|September 10, 2009
High-dose zoledronic acid impacts bone remodeling with effects on osteoblastic lineage and bone mechanical propertiesSamantha Pozzi, Sonia Vallet, Siddhartha Mukherjee, et al.Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|March 25, 2011
Antimyeloma activity of a multitargeted kinase inhibitor, AT9283, via potent Aurora kinase and STAT3 inhibition either alone or in combination with lenalidomideLoredana Santo, Teru Hideshima, Diana Cirstea, et al.Proceedings of the National Academy of Sciences of the United States of America|December 30, 2003
Transcriptional signature of histone deacetylase inhibition in multiple myeloma: biological and clinical implicationsConstantine S Mitsiades, Nicholas S Mitsiades, Ciaran J McMullan, et al.The Lancet. Haematology|December 22, 2015
Elotuzumab in combination with lenalidomide and dexamethasone in patients with relapsed multiple myeloma: final phase 2 results from the randomised, open-label, phase 1b-2 dose-escalation studyPaul G Richardson, Sundar Jagannath, Philippe Moreau, et al.Pageof 79